SOHO 2023 | Ponatinib for CML and Ph+ ALL: five-year results from the PACE trial
Hagop Kantarjian
• 6 Sep 2023
Hagop Kantarjian, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the five-year results of the PACE trial (NCT01207440), highlighting the promising efficacy of ponatinib as a third-generation TKI for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study results also show that the dosage of ponatinib can be reduced in many cases, lowering the risk of toxicity. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
